Koselugo (selumetinib)

News alerts, weekly reports and conference planners

Company:

AstraZeneca, Merck (MSD), Pfizer

Drug class:

MEK inhibitor

Related drugs:

BRAF V600E	Glioma	BRAF V600E	Glioma	selumetinib Sensitive: A2 - Guideline selumetinib Sensitive : A2	selumetinib Sensitive: A2 - Guideline selumetinib Sensitive : A2
BRAF fusion	Glioma	BRAF fusion	Glioma	selumetinib Sensitive: A2 - Guideline selumetinib Sensitive : A2	selumetinib Sensitive: A2 - Guideline selumetinib Sensitive : A2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	selumetinib Sensitive: B - Late Trials selumetinib Sensitive : B	selumetinib Sensitive: B - Late Trials selumetinib Sensitive : B
BRAF V600E	Astrocytoma	BRAF V600E	Astrocytoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
NF1 mutation	CNS Tumor	NF1 mutation	CNS Tumor	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
KIAA1549-BRAF fusion	Astrocytoma	KIAA1549-BRAF fusion	Astrocytoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	afatinib + selumetinib Sensitive: C2 – Inclusion Criteria afatinib + selumetinib Sensitive : C2	afatinib + selumetinib Sensitive: C2 – Inclusion Criteria afatinib + selumetinib Sensitive : C2
KIAA1549-BRAF fusion	Glioma	KIAA1549-BRAF fusion	Glioma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
BRAF mutation	Thyroid Gland Carcinoma	BRAF mutation	Thyroid Gland Carcinoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
GNAQ mutation	Melanoma	GNAQ mutation	Melanoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
NRAS mutation	Thyroid Gland Carcinoma	NRAS mutation	Thyroid Gland Carcinoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	cetuximab + selumetinib Sensitive: C2 – Inclusion Criteria cetuximab + selumetinib Sensitive : C2	cetuximab + selumetinib Sensitive: C2 – Inclusion Criteria cetuximab + selumetinib Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + selumetinib Sensitive: C2 – Inclusion Criteria osimertinib + selumetinib Sensitive : C2	osimertinib + selumetinib Sensitive: C2 – Inclusion Criteria osimertinib + selumetinib Sensitive : C2
BRAF wild-type	Melanoma	BRAF wild-type	Melanoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
KRAS G12R	Pancreatic Adenocarcinoma	KRAS G12R	Pancreatic Adenocarcinoma	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
KRAS G12S	Biliary Tract Cancer	KRAS G12S	Biliary Tract Cancer	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
KRAS G12D	Biliary Tract Cancer	KRAS G12D	Biliary Tract Cancer	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
BRAF mutation + NF1 mutation	Melanoma	BRAF mutation + NF1 mutation	Melanoma	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3
BRAF mutation + EGFR mutation	Melanoma	BRAF mutation + EGFR mutation	Melanoma	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3
BRAF mutation + MAP2K1 mutation	Melanoma	BRAF mutation + MAP2K1 mutation	Melanoma	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3
MAP2K1 P124L	Melanoma	MAP2K1 P124L	Melanoma	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3
MAP2K1 K57N	Melanoma	MAP2K1 K57N	Melanoma	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3
BRAF mutation	Melanoma	BRAF mutation	Melanoma	selumetinib + RTB101 Sensitive: C3 – Early Trials selumetinib + RTB101 Sensitive : C3	selumetinib + RTB101 Sensitive: C3 – Early Trials selumetinib + RTB101 Sensitive : C3
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
GNA11 Q209L	Uveal Melanoma	GNA11 Q209L	Uveal Melanoma	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
DDX43 overexpression	Uveal Melanoma	DDX43 overexpression	Uveal Melanoma	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3
KRAS overexpression	Uveal Melanoma	KRAS overexpression	Uveal Melanoma	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3
NRAS overexpression	Uveal Melanoma	NRAS overexpression	Uveal Melanoma	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3

Koselugo (selumetinib)

Associations
(106)

Associations
(106)

Koselugo (selumetinib)

Associations(106)

Associations(106)

Associations
(106)

Associations
(106)